Cognitive Behavioral Therapy Improves Insomnia in Patients with Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, cognitive behavioral therapy for insomnia significantly improves sleep quality and insomnia in patients with cancer, while armodafinil, a wakefulness-promoting agent, did not.
For the study, researchers sought to investigate the use of cognitive behavioral therapy for insomnia plus armodafinil would result in improved insomnia control in cancer survivors compared with cognitive behavioral therapy alone. The researchers enrolled 96 cancer survivors with an average age of 56 years.
Of those, 87.5% were female and 68% had breast cancer. Participants were randomly assigned to receive cognitive behavioral therapy for insomnia plus armodafinil or placebo, armodafinil alone, or placebo alone. Each intervention was administered for 7 weeks.
Results showed that both cognitive behavioral therapy for insomnia plus armodafinil (P = 0.001) and cognitive behavioral therapy plus placebo (P = 0.010) significantly reduced the severity of insomnia compared with placebo alone. Similar results were observed in regard to sleep quality and improvements in both areas continued 3 months following treatment. However, behavioral therapy plus armodafinil was not significantly better than behavioral therapy plus placebo (P = 0.421). Armodafinil alone was not significant better than placebo alone (P = 0.584). The findings suggest that cognitive behavioral therapy for insomnia alone improved the severity of insomnia and sleep quality the most.
Cognitive behavioral therapy for insomnia significantly improves sleep quality and insomnia in patients with cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer